| Chronic immune-related adverse events following adjuvant anti–PD-1 therapy for high-risk resected melanoma JR Patrinely, R Johnson, AR Lawless, P Bhave, A Sawyers, M Dimitrova, ... JAMA oncology 7 (5), 744-748, 2021 | 146 | 2021 |
| Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma CN Owen, X Bai, T Quah, SN Lo, C Allayous, S Callaghan, ... Annals of Oncology 32 (7), 917-925, 2021 | 107 | 2021 |
| Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders LJ Brown, A Weppler, P Bhave, C Allayous, JR Patrinely Jr, P Ott, ... Journal for ImmunoTherapy of Cancer 9 (5), 2021 | 47 | 2021 |
| Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis P Bhave, L Pallan, GV Long, AM Menzies, V Atkinson, JV Cohen, ... British Journal of Cancer 124 (3), 574-580, 2021 | 46 | 2021 |
| Mortality due to immunotherapy related hepatitis P Bhave, A Buckle, S Sandhu, S Sood Journal of hepatology 69 (4), 976-978, 2018 | 43 | 2018 |
| Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy BR Halle, AB Warner, FY Zaman, A Haydon, P Bhave, AK Dewan, F Ye, ... Journal for immunotherapy of cancer 9 (10), 2021 | 41 | 2021 |
| Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study F Dimitriou, K Namikawa, ILM Reijers, EI Buchbinder, JA Soon, ... Annals of Oncology 33 (9), 968-980, 2022 | 35 | 2022 |
| Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma P Bhave, T Ahmed, SN Lo, A Shoushtari, A Zaremba, JM Versluis, ... Journal for immunotherapy of cancer 10 (7), 2022 | 28 | 2022 |
| A guide to performing cardiac surgery in patients with hereditary bleeding disorders P Bhave, D McGiffin, J Shaw, M Walsh, P McCarthy, H Tran, AK Davis Journal of Cardiac Surgery: Including Mechanical and Biological Support for …, 2015 | 28 | 2015 |
| Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES) PKH Lau, B Feran, L Smith, A Lasocki, R Molania, K Smith, A Weppler, ... Journal for Immunotherapy of Cancer 9 (10), 2021 | 20 | 2021 |
| The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis JM Versluis, AM Hendriks, AM Weppler, LJ Brown, K de Joode, ... European Journal of Cancer 151, 72-83, 2021 | 18 | 2021 |
| Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases ML Hilbers, F Dimitriou, P Lau, P Bhave, GA McArthur, L Zimmer, ... European Journal of Cancer 156, 149-163, 2021 | 12 | 2021 |
| Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma AM Weppler, A Pattison, P Bhave, P De Ieso, J Raleigh, A Hatzimihalis, ... Journal for Immunotherapy of Cancer 8 (2), 2020 | 11 | 2020 |
| Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy P Bhave, A Hong, SN Lo, R Johnson, J Mangana, DB Johnson, O Dulgar, ... Journal for ImmunoTherapy of Cancer 11 (3), 2023 | 8 | 2023 |
| Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti–PD-1 therapy A Hepner, VG Atkinson, J Larkin, RA Burrell, MS Carlino, DB Johnson, ... European Journal of Cancer 153, 213-222, 2021 | 8 | 2021 |
| Melanoma recurrence after adjuvant targeted therapy: A multicenter analysis. P Bhave, L Pallan, V Atkinson, JV Cohen, V Chiarion-Sileni, M Nyakas, ... Journal of Clinical Oncology 38 (15_suppl), 10016-10016, 2020 | 7 | 2020 |
| Intraperitoneal meropenem for peritoneal dialysis peritonitis with Serratia marcescens immediately on commencing dialysis P Bhave, P Tregaskis, R Walker, S Wilson New Microbes and New Infections 10, 84-86, 2016 | 7 | 2016 |
| Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy SK Jacques, J McKeown, P Grover, DB Johnson, A Zaremba, F Dimitriou, ... European Journal of Cancer 199, 113563, 2024 | 6 | 2024 |
| Management of cutaneous melanoma in Australia: a narrative review. P Bhave, J Wong, A McInerney‐Leo, AE Cust, C Lawn, M Janda, VJ Mar Medical Journal of Australia 218 (9), 2023 | 6 | 2023 |
| Treatment of high risk resected melanoma in Australia: current landscape and practises P Bhave, A Haydon Australasian Journal of Dermatology 61 (3), 203-209, 2020 | 6 | 2020 |
